Movement disorders in childhood: therapeutic update

被引:3
作者
Roubertie, A [1 ]
Leydet, J [1 ]
Rivier, F [1 ]
Humbertclaude, V [1 ]
Cheminal, R [1 ]
Echenne, B [1 ]
机构
[1] Hop St Eloi, Serv Neuropediat, F-34295 Montpellier 5, France
来源
ARCHIVES DE PEDIATRIE | 2004年 / 11卷 / 08期
关键词
movement disorders; dystonia; Tourette syndrome; botulinum toxin; drug therapy; baclofen; intrathecal injections; neurosurgery; electric stimulation therapy; child;
D O I
10.1016/j.arcped.2004.01.009
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Abnormal movements are not uncommon in childhood. Due to the severity of the abnormal movements or to the functional disability, a medical treatment is often required: the wide range of available pharmacological molecules and the absence of therapeutic consensus highlight the limited efficacy of the medical treatment on dystonic or athetoid movements, or severe tic disorders. The recent identification of the enzymatic defect implicated in metabolic diseases led to the development of specific treatment for newly recognized disorders, with more or less interesting results (creatine ou biotine supplementation). Recent progress in functional neurosurgery opened new fields in the treatment of movement disorders. Intrathecal baclofen was proved effective in the treatment of secondary dystonia, especially in patients with cerebral palsy. Deep brain stimulation is now an established therapy for patients with a generalized dystonic syndrome. Given the successful results of pallidal stimulation in dystonia, the indication of this procedure has been discussed in other types of abnormal movements. (C) 2003 Elsevier SAS. Tous droits reserves.
引用
收藏
页码:951 / 954
页数:4
相关论文
共 25 条
  • [11] Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.
    Hayflick, SJ
    Westaway, SK
    Levinson, B
    Zhou, B
    Johnson, MA
    Ching, KHL
    Gitschier, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) : 33 - 40
  • [12] Torsion dystonia in children
    Vanessa K. Hinson
    Christopher G. Goetz
    [J]. Current Treatment Options in Neurology, 2003, 5 (4) : 291 - 297
  • [13] KUPSCH A, 2003, J NEUROL S1, V250, P147
  • [14] LACONO RP, 1996, PEDIATR NEUROL, V14, P145
  • [15] Tourette's syndrome
    Leckman, JF
    [J]. LANCET, 2002, 360 (9345) : 1577 - 1586
  • [16] Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:: A 6-week randomized trial
    Müller-Vahl, KR
    Schneider, U
    Prevedel, H
    Theloe, K
    Kolbe, H
    Daldrup, T
    Emrich, HM
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (04) : 459 - 465
  • [17] RETRACTED: A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder (Retracted Article. See vol 18, 2004)
    Niederhofer, H
    Staffen, W
    Mair, A
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (01) : 113 - 119
  • [18] Biotin-responsive basal ganglia disease: a novel entity
    Ozand, PT
    Gascon, GG
    Al Essa, M
    Joshi, S
    Al Jishi, E
    Bakheet, S
    Al Watban, J
    Al-Kawi, MZ
    Dabbagh, O
    [J]. BRAIN, 1998, 121 : 1267 - 1279
  • [19] A placebo-controlled trial of risperidone in Tourette syndrome
    Scahill, L
    Leckman, JF
    Schultz, RT
    Katsovich, L
    Peterson, BS
    [J]. NEUROLOGY, 2003, 60 (07) : 1130 - 1135
  • [20] STOCKLER S, 1994, PEDIATR RES, V36, P409